Table 1 Association between CMTM6 expression and clinicopathological variables in HER2+ BC
From: CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Characteristic | Low expression of CMTM6 | High expression of CMTM6 | P value |
|---|---|---|---|
n | 29 | 47 | Â |
T stage, n (%) | Â | Â | 0.007 |
 T1 | 10 (13.2%) | 9 (11.8%) |  |
 T2 | 11 (14.5%) | 25 (32.9%) |  |
 T3 | 5 (6.6%) | 5 (6.6%) |  |
 T4 | 3 (3.9%) | 8 (10.5%) |  |
N stage, n (%) | Â | Â | 0.039 |
 N0 | 11 (14.5%) | 13 (17.1%) |  |
 N1 | 14 (18.4%) | 23 (30.3%) |  |
 N2 | 3 (3.9%) | 6 (7.9%) |  |
 N3 | 1 (1.3%) | 5 (6.5%) |  |
M stage, n (%) | Â | Â | 0.023 |
 M0 | 27(35.5%) | 40 (52.7%) |  |
 M1 | 2 (2.6%) | 7 (9.2%) |  |
Pathologic stage, n (%) | Â | Â | 0.041 |
 Stage I | 12 (15.8%) | 2 (2.6%) |  |
 Stage II | 14 (18.4%) | 31 (40.8%) |  |
 Stage III | 2 (2.6%) | 11 (14.5%) |  |
 Stage IV | 1 (1.3%) | 3 (3.9%) |  |
Age, n (%) | Â | Â | 0.473 |
  < =60 | 15 (19.7%) | 22 (28.9%) |  |
  > 60 | 14 (18.4%) | 25 (32.9%) |  |
PR status, n (%) | Â | Â | 0.222 |
 Negative | 12 (15.8%) | 23 (30.3%) |  |
 Positive | 17 (22.4%) | 24 (31.5%) |  |
ER status, n (%) | Â | Â | 0.016 |
 Negative | 18 (23.7%) | 10 (13.2%) |  |
 Positive | 11 (14.5%) | 37 (48.7%) |  |
Relapse status, n (%) |  |  | < 0.001 |
 No | 26 (34.2%) | 25 (32.9%) |  |
 Yes | 3 (3.9%) | 22 (28.9%) |  |
Survival status, n (%) |  |  | < 0.001 |
 Alive | 20 (26.3%) | 19 (25%) |  |
 Dead | 9 (11.8%) | 28 (36.8%) |  |